Document ID: chunk:federal_register_of_legislation:F2024L01703:front:0:p2
Version: federal_register_of_legislation:F2024L01703
Segment Type: other
Provision Reference: 
Character Range: 3103–6390

Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Death from peritoneal adhesions
 1.           For the purposes of this Statement of Principles, peritoneal adhesions, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's peritoneal adhesions.
Note: terminal event is defined in the Schedule 1 – Dictionary.
 1.                Basis for determining the factors
The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that peritoneal adhesions and death from peritoneal adhesions can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.
Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.
 1.                Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting peritoneal adhesions or death from peritoneal adhesions with the circumstances of a person's relevant service:
 1.           having peritonitis at least 3 days before clinical onset;
 2.           having one of the following diseases at least 3 days before clinical onset:
         1.           appendicitis;
         2.           cholecystitis;
         3.           diverticulitis;
         4.           endometriosis;
         5.           inflammatory bowel disease;
         6.            pancreatitis;
         7.           pelvic inflammatory disease.
 3.           having intra-abdominal or pelvic surgery at least 3 days before clinical onset;
 4.           having penetrating trauma to the abdomen that enters the peritoneal cavity at least 3 days before clinical onset;
 5.           undergoing a course of ablative radiotherapy for cancer, where the abdominopelvic region was in the field of radiation, at least 3 days before clinical onset;
 6.           having a bacterial, fungal or Echinococcus granulosus infection involving the peritoneal cavity at least 3 days before clinical onset;
 7.           having a perforation of the hollow viscus into the peritoneal cavity at least 3 days before clinical onset;
Note: A perforated hollow viscus could include a perforated stomach, gallbladder, intestine, appendix, renal pelvis, ureter, bladder, or uterus.
 1.           undergoing peritoneal dialysis for at least 6 months duration before clinical onset;
 2.           undergoing intraperitoneal chemotherapy with cisplatin, oxaliplatin, carboplatin, 5-fluorouracil, mitoxantrone (mitozantrone), or mitomycin C at least 3 days before clinical onset;
 3.       having a primary or secondary malignant neoplasm involving the peritoneum at least 3 days before clinical onset;
 4.       having an ovarian dermoid cyst rupturing into the peritoneum at least 3 days before clinical onset;
 5.       having a ventriculoperitoneal shunt at least 3 days before clinical onset;
 6.       having a peritoneovenous shunt at least 3 days before the clinical onset of encapsulating peritoneal sclerosis;
 7.       having hernia mesh inserted in the abdomen at the site of the subsequent peritoneal